title: [Effects of SERM on breast cancer and cardiovascular disease: making a comparison between raloxifene use and hormone replacement therapy on the risks of the diseases].
abstract: According to the report of MORE trial, raloxifene (RLX) compensate for the faults of hormone replacement therapy with the reasons following below; 1) RLX inhibits onset of breast cancer with estrogen receptor remarkably, 2) RLX inhibits onset of cardiovascular disease in its high risk group. However, because RLX has a elevated risk of venous thrombosis as same as hormone replacement therapy, we should give attention to this disease at the use of RLX.
authors.affiliation: Department of OB/GYN, Hirosaki University School of Medicine.
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Higuchi
authors.forename: Hideki
authors.initials: H
authors.lastname: Mizunuma
mesh_terms: D001943:Breast Neoplasms / Q000139:chemically induced / Q000378:metabolism / Q000517:prevention & control*; D002318:Cardiovascular Diseases / Q000139:chemically induced / Q000517:prevention & control*; D015914:Estrogen Replacement Therapy / Q000009:adverse effects; D005260:Female; D006801:Humans; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy*; D020849:Raloxifene Hydrochloride / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D011960:Receptors, Estrogen / Q000037:antagonists & inhibitors / Q000378:metabolism; D012306:Risk; D020845:Selective Estrogen Receptor Modulators / Q000009:adverse effects / Q000627:therapeutic use*; D020246:Venous Thrombosis / Q000139:chemically induced
chemical_list: D011960:Receptors, Estrogen; D020845:Selective Estrogen Receptor Modulators; D020849:Raloxifene Hydrochloride